Duprez Wilko, Premkumar Lakshmanane, Halili Maria A, Lindahl Fredrik, Reid Robert C, Fairlie David P, Martin Jennifer L
Institute for Molecular Bioscience, Division of Chemistry and Structural Biology, University of Queensland , Brisbane, Queensland 4072, Australia.
J Med Chem. 2015 Jan 22;58(2):577-87. doi: 10.1021/jm500955s. Epub 2014 Dec 18.
One approach to address antibiotic resistance is to develop drugs that interfere with bacterial virulence. A master regulator of virulence in Gram-negative bacteria is the oxidative folding machinery comprising DsbA and DsbB. A crystal structure at 2.5 Å resolution is reported here for Escherichia coli DsbA complexed with PFATCDS, a heptapeptide derived from the partner protein Escherichia coli DsbB. Details of the peptide binding mode and binding site provide valuable clues for inhibitor design. Structure-activity relationships for 30 analogues were used to produce short peptides with a cysteine that bind tightly to EcDsbA (Kd = 2.0 ± 0.3 μM) and inhibit its activity (IC50 = 5.1 ± 1.1 μM). The most potent inhibitor does not bind to or inhibit human thioredoxin that shares a similar active site. This finding suggests that small molecule inhibitors can be designed to exploit a key interaction of EcDsbA, as the basis for antivirulence agents with a novel mechanism of action.
解决抗生素耐药性的一种方法是开发干扰细菌毒力的药物。革兰氏阴性菌中毒力的主要调节因子是由DsbA和DsbB组成的氧化折叠机制。本文报道了大肠杆菌DsbA与PFATCDS(一种源自伴侣蛋白大肠杆菌DsbB的七肽)复合的2.5埃分辨率晶体结构。肽结合模式和结合位点的细节为抑制剂设计提供了有价值的线索。利用30种类似物的构效关系来制备带有半胱氨酸的短肽,这些短肽与EcDsbA紧密结合(Kd = 2.0 ± 0.3 μM)并抑制其活性(IC50 = 5.1 ± 1.1 μM)。最有效的抑制剂不与具有相似活性位点的人硫氧还蛋白结合或抑制其活性。这一发现表明,可以设计小分子抑制剂来利用EcDsbA的关键相互作用,作为具有新型作用机制的抗毒力药物的基础。